Management of Heart Failure
Authors:
Open Access
- 4 October 2022
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 328 (13) , 1346-1347
Abstract
Since the 2017 publication of the ACC/AHA/HFSA focused update of HF guidelines, multiple clinical trials have demonstrated the significant benefits of novel medical therapies for patients with HF across the spectrum of EF.1-4 The emergence of these therapies adds nuance and complexity to the care of patients with HF.Keywords
This publication has 10 references indexed in Scilit:
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart FailureJACC, 2022
- In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection FractionJACC, 2021
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine, 2021
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine, 2020
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsThe Lancet, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trialThe Lancet, 2019
- Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During HospitalizationJACC: Heart Failure, 2019
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2017
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014